VERTEX PHARMACEUTICALS INC / MA Proceeds from (Repayments of) Restricted Cash, Financing Activities
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Proceeds from (Repayments of) Restricted Cash, Financing Activities of $31.80 million for the 9-month period ending 2013-09-30, per its 10-Q filed 2013-11-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities · last filed 2013-11-07
- VERTEX PHARMACEUTICALS INC / MA proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2013-09-30 was $0.00.
| Period end | Proceeds from (Repayments of) Restricted Cash, Financing Activities 3 month | Proceeds from (Repayments of) Restricted Cash, Financing Activities 6 month | Proceeds from (Repayments of) Restricted Cash, Financing Activities 9 month |
|---|---|---|---|
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $31.80M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $31.80M 10-Q · filed 2013-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |